GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhongzhi Pharmaceutical Holdings Ltd (HKSE:03737) » Definitions » Owner Earnings per Share (TTM)

Zhongzhi Pharmaceutical Holdings (HKSE:03737) Owner Earnings per Share (TTM) : 0.05 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Zhongzhi Pharmaceutical Holdings Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Zhongzhi Pharmaceutical Holdings's Owner Earnings per Share (TTM) ended in Dec. 2023 was HK$0.05. It's Price-to-Owner-Earnings ratio for today is 23.6.


The historical rank and industry rank for Zhongzhi Pharmaceutical Holdings's Owner Earnings per Share (TTM) or its related term are showing as below:

HKSE:03737' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.32   Med: 9.58   Max: 28.4
Current: 23.4


During the past 10 years, the highest Price-to-Owner-Earnings ratio of Zhongzhi Pharmaceutical Holdings was 28.40. The lowest was 3.32. And the median was 9.58.


HKSE:03737's Price-to-Owner-Earnings is ranked better than
58.19% of 421 companies
in the Drug Manufacturers industry
Industry Median: 28.28 vs HKSE:03737: 23.40

Zhongzhi Pharmaceutical Holdings's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$0.03. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.21. It's PE Ratio ratio for today is 5.67.

Zhongzhi Pharmaceutical Holdings's EPS without NRI for the six months ended in Dec. 2023 was HK$0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.21. It's PE Ratio without NRI ratio for today is 5.70.


Zhongzhi Pharmaceutical Holdings Owner Earnings per Share (TTM) Historical Data

The historical data trend for Zhongzhi Pharmaceutical Holdings's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongzhi Pharmaceutical Holdings Owner Earnings per Share (TTM) Chart

Zhongzhi Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.10 0.17 0.30 0.05

Zhongzhi Pharmaceutical Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 - 0.30 - 0.05

Competitive Comparison of Zhongzhi Pharmaceutical Holdings's Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, Zhongzhi Pharmaceutical Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhongzhi Pharmaceutical Holdings's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhongzhi Pharmaceutical Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Zhongzhi Pharmaceutical Holdings's Price-to-Owner-Earnings falls into.



Zhongzhi Pharmaceutical Holdings Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Zhongzhi Pharmaceutical Holdings's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 178
Depreciation, Depletion and Amortization 112
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 90
Change In Working Capital -158
Shares Outstanding (Diluted Average) 847

1. Start with "Net Income" from income statement. Zhongzhi Pharmaceutical Holdings's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$178 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Zhongzhi Pharmaceutical Holdings's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2023 was HK$112 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Zhongzhi Pharmaceutical Holdings's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = HK$90 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Zhongzhi Pharmaceutical Holdings's 5-Year Average Maintenance Capital Expenditure = HK$90 Mil

5. "Change In Working Capital" is from cashflow statement. Zhongzhi Pharmaceutical Holdings's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-158 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Zhongzhi Pharmaceutical Holdings's Shares Outstanding (Diluted Average) for the months ended in Dec. 2023 was 846.999 Mil.

Zhongzhi Pharmaceutical Holdings's Onwer Earnings Per Share for Dec. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 178.04 +111.652+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-89.9152+-157.95)/846.999
=0.05

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=1.18/0.05
=23.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Zhongzhi Pharmaceutical Holdings Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Zhongzhi Pharmaceutical Holdings's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhongzhi Pharmaceutical Holdings (HKSE:03737) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Kangtai Road South, Torch Development Zone, Guangdong Province, Zhongshan, CHN
Zhongzhi Pharmaceutical Holdings Ltd is engaged in the business of manufacturing and selling pharmaceutical products. The group's operations can be divided into three segments, namely Pharmaceutical manufacturing, Operation of chain pharmacies, and Operation of online pharmacies in Zhongshan in the Guangdong province, the PRC. In the Pharmaceutical manufacturing segment, the company is engaged in the research and development, manufacturing and sale of Chinese patent medicines. In the Operation of chain pharmacies segment, the firm operates chain pharmacies in Zhongshan under the brand Zeus for the sale of pharmaceutical products. The Operation of online pharmacies segment sells medicines online. It derives a majority of its revenue from the PRC.

Zhongzhi Pharmaceutical Holdings (HKSE:03737) Headlines

No Headlines